You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
港股異動丨復星醫藥A+H股齊漲 鹽酸乙胺丁醇片通過仿製藥一致性評價
格隆匯 08-04 10:48
格隆匯8月4日丨復星醫藥A+H股齊漲,復星醫藥(02196.HK)漲4.68%,股價創近兩年來新高;復星醫藥(600196.SH)大漲約7%,股價創歷史新高,今年迄今累計漲幅達到177%。復星醫藥昨日公佈,近日,公司控股子公司瀋陽紅旗製藥有限公司收到國家藥品監督管理局頒發的關於鹽酸乙胺丁醇片的《藥品補充申請批准通知書》,該藥品通過仿製藥一致性評價。此前,公司控股子公司上海復星醫藥產業發展有限公司(以下簡稱“復星醫藥產業”)收到國家藥品監督管理局關於其獲許可的新型冠狀病毒mRNA疫苗(BNT162b1)用於預防新型冠狀病毒肺炎的臨牀試驗批准。復星醫藥產業擬於條件具備後於中國大陸開展該疫苗的I期臨牀試驗。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account